• Drugs Made In America Acquisition updated engagement terms for CFO Saleem Elmasri on April 22, 2026, keeping monthly compensation at $3,500.
• Outstanding amounts under Elmasri’s services arrangement remain unpaid, continuing to accrue as company obligations.
• Elmasri became entitled to 175,000 ordinary shares, earned upon execution of a definitive agreement.
• Separate April 22, 2026 agreement set CEO Roger E. Bendelac compensation at $4,500 per month, with $2,500 payable currently.
• Bendelac also became entitled to 250,000 ordinary shares, to be issued at closing of initial business combination within 10 days.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Drugs Made In America Acquisition Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-048585), on April 28, 2026, and is solely responsible for the information contained therein.